Relative Risk of Peripheral Neuropathy With Ado-Trastuzumab Emtansine (T-DM1) Compared to Taxane-Based Regimens in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Cancers: A Systematic Review and Meta-Analysis.

Jahan, Nusrat; Rehman, Shabnam; Khan, Rafiullah; Jones, Catherine

Jahan, Nusrat; Rehman, Shabnam; Khan, Rafiullah; Jones, Catherine.

Affiliation

Jahan N; Division of Hematology and Oncology, Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.
Rehman S; Division of Hematology and Oncology, Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.
Khan R; Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, USA.
Jones C; Division of Hematology and Oncology, Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.

Cureus ; 13(5): e15282, 2021 May 27.

Article in En | MEDLINE | ID: mdl-34194883

Key words

ado-trastuzumab emtansine; docetaxel; paclitaxel; peripheral neuropathy; peripheral sensory neuropathy; t-dm1; taxane; trastuzumab emtansine

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Language: En Journal: Cureus Year: 2021 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google